Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.42 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.42 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.42 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833388 | 0.91 | ADORA1 (0.65) | ADORA1ALDH1A1HTTEEDRBBP4 | |
| SCHEMBL17798700 | 0.87 | EED (0.49) | ADORA1ALDH1A1EEDRBBP4SUZ12 | |
| SCHEMBL28457125 | 0.84 | ALDH1A1 (0.49) | ADORA1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL6421704 | 0.82 | ADORA1 (0.48) | ADORA1ALDH1A1ESR2SMN1; SMN2MAPT | |
| SCHEMBL29977848 | 0.80 | ADORA1 (0.45) | ADORA1ALDH1A1EEDRBBP4SUZ12 | |
| SCHEMBL17377231 | 0.79 | ADORA1 (0.48) | ADORA1ESR2SMN1; SMN2MAPTNR1H2 | |
| SCHEMBL21669702 | 0.79 | ADORA1 (0.46) | ADORA1ESR2MAPTNR1H2KDM4E | |
| SCHEMBL27076948 | 0.78 | ADORA1 (0.53) | ADORA1EEDRBBP4SUZ12EZH2 | |
| SCHEMBL22482028 | 0.77 | ADORA1 (0.56) | ADORA1ALDH1A1HTTESR2MEN1 | |
| SCHEMBL20558294 | 0.77 | ADORA1 (0.51) | ADORA1ALDH1A1ESR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-3830087-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2023-05-24 | — | — | EP | disclosed |
| EP-3830087-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2022-12-20 | — | — | US | disclosed |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2022-12-20 | — | — | US | disclosed |
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2021-09-09 | — | — | US | disclosed |
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2021-09-09 | — | — | US | disclosed |
| CN-107922430-B | 2-substituted benzimidazole-4-formamide compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-09-04 | — | — | CN | disclosed |
| WO-2020025587-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | NQO1, ALPI, LCT | ADORA1 3150/4885ALDH1A1 224/4885HTT 4378/4885 |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | HRH4, HNMT, NNT | ADORA1 1840/4885ALDH1A1 2633/4885HTT 97/4885 |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, ALPI, LCT | ADORA1 3150/4885ALDH1A1 224/4885HTT 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.